Table 1.
General characteristics of the populations reviewed
| Sample size | Age, y | Male | HT | DM | COPD | CKD | Obesity | HF | Cancer | CVD | FU, mo | NOS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohen et al.10 | 2,895,943 | 75.7 | 1,227,545 (42.0) | 2,081,772 (72.0) | 938,043 (32.7) | 578,650 (20)∗ | 528,314 (14.0) | 478,902 (17.0) | 334,654 (12) | 418,700 (14.4) | 364,782 (13.0) | 4 | 8 |
| Wang et al.11 | 2,940,988 | 43.8 | 1,241,483 (42.2) | 440,998 (14.9) | 188,488 (6.4)† | 51,592 (1.7) | 59177 (2.0) | 286,338 (9.7)† | NR | NR | NR | 12 | 7 |
| Xie et al.12 | 5,791,407 | 62.5 | 5,228,431 (90.2) | 1,525,944 (26.3) | 1,321,907 (22.8) | 633,000 (10.9) | 970,057 (16.7) | 2,462.44 (42.5) | NR | 357,192 (6.1) | NR | 12 | 8 |
| Daugherty et al.13 | 9,247,505 | 42.4 | 4,640,393 (50.2) | NR | 521,699 (5.6) | NR | NR | NR | NR | NR | NR | 6 | 6 |
Values in parentheses are %.
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; DM, diabetes mellitus; FU, follow-up; HF, heart failure; HT, arterial hypertension; NOS, Newcastle-Ottawa quality assessment scale; NR, not reported.
∗
Defined as chronic pulmonary disease.
†
Only DM type 2.